CanBas Co Ltd (4575)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:CanBas Co Ltd (4575) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013096
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CanBas Co Ltd (CanBas) is a clinical stage biopharmaceutical company that provides drugs. The company discovers and develops of novel therapeutics in the field of oncology targeting the cell cycle. It product under development is CBP501, a modified synthetic peptide enhancing the efficacy of cisplatin without adding toxicity. CanBas’ CBP501 is in US Phase II development for first-line treatment of late stage malignant pleural mesothelioma and non-small cell lung cancer. The company’s other drug candidates, CBS9106, an orally-active synthetic small molecule of molecular mass 420, is in preclinical stage, and CBS2400 program is currently in the lead optimization stage of development. It also develops techniques to determine the drug specific sensitivity of individual cancer from a patient. CanBas is headquartered in Numazu, Japan.

CanBas Co Ltd (4575) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
CanBas Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
CanBas Enters into Research Agreement with Fujifilm 10
CanBas Enters into Research Agreement with University of Shizuoka 11
Licensing Agreements 12
Stemline Therapeutics Enters into Licensing Agreement with CanBas 12
Stemline Therapeutics Enters into Licensing Agreement with CanBas for CBS-9106 13
CanBas Co Ltd – Key Competitors 14
CanBas Co Ltd – Key Employees 15
CanBas Co Ltd – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Clinical Trials 17
Feb 21, 2017: Stemline Therapeutics Provides Update on SL-801 17
May 03, 2016: Stemline Therapeutics Clears First Cohort of Patients in Ongoing SL-801 Phase 1 Trial 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
CanBas Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
CanBas Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
CanBas Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
CanBas Enters into Research Agreement with Fujifilm 10
CanBas Enters into Research Agreement with University of Shizuoka 11
Stemline Therapeutics Enters into Licensing Agreement with CanBas 12
Stemline Therapeutics Enters into Licensing Agreement with CanBas for CBS-9106 13
CanBas Co Ltd, Key Competitors 14
CanBas Co Ltd, Key Employees 15

★海外企業調査レポート[CanBas Co Ltd (4575)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bharat Heavy Electricals Ltd:企業の戦略・SWOT・財務分析
    Bharat Heavy Electricals Ltd - Strategy, SWOT and Corporate Finance Report Summary Bharat Heavy Electricals Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Lukoil Oil Co (LKOH)-エネルギー分野:企業M&A・提携分析
    Summary Lukoil Oil Company (Lukoil) is a vertically integrated oil and gas company, which carries out exploration and production of crude oil and natural gas. Lukoil has interest in properties across Russia, Azerbaijan, Kazakhstan, Uzbekistan, the Middle East, South America, Northern and Western Afr …
  • Touchstone Group plc:企業の戦略的SWOT分析
    Touchstone Group plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Decmil Group Ltd (DCG):企業の財務・戦略的SWOT分析
    Summary Decmil Group Ltd (Decmil), is a provider of construction, engineering and accommodation and project management services. The company provides services such as design, accommodation services, civil engineering, construction, and maintenance services, among others. Decmil provides government i …
  • New Zealand Post Ltd:企業の戦略的SWOT分析
    New Zealand Post Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • AVJennings Limited:企業の戦略・SWOT・財務情報
    AVJennings Limited - Strategy, SWOT and Corporate Finance Report Summary AVJennings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Eddingpharm Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Eddingpharm Inc (Eddingpharm) is a pharmaceutical company that manufactures and distributes medicines. The company develops products in therapeutic areas such as clinical nutrition, antibiotics, respiratory system, nephrology and cardiovascular. It offers antibiotics including vancocin, cecl …
  • Tianjin Chase Sun Pharmaceutical Co Ltd (300026):企業の財務・戦略的SWOT分析
    Summary Tianjin Chase Sun Pharmaceutical Co Ltd (Chase Sun) is a medicine and health industry group. The company research, develops, produces, and markets various pharmaceutical products. It offers products such as Chinese herb preparations, Chinese medicinal granules, synthetic drugs, biotech drugs …
  • CLP Holdings Ltd (2)-エネルギー分野:企業M&A・提携分析
    Summary CLP Holdings Limited (CLP) is an investor and operator in the energy sector of Asia Pacific region. The company invests in power generation, transmission and distribution, and electricity and gas retail activities. Its portfolio includes equity generating and purchase capacities. CLP’s gener …
  • FANUC CORPORATION:企業の戦略・SWOT・財務分析
    FANUC CORPORATION - Strategy, SWOT and Corporate Finance Report Summary FANUC CORPORATION - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Brambles Limited (BXB):企業の財務・戦略的SWOT分析
    Brambles Limited (BXB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Estel Technologies Pvt. Ltd:企業の戦略的SWOT分析
    Estel Technologies Pvt. Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Lear Corporation:企業の戦略・SWOT・財務分析
    Lear Corporation - Strategy, SWOT and Corporate Finance Report Summary Lear Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • IFFCO-Tokio General Insurance Co. Ltd.:企業の戦略・SWOT・財務情報
    IFFCO-Tokio General Insurance Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary IFFCO-Tokio General Insurance Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Swelect Energy Systems Ltd (SWELECTES):企業の財務・戦略的SWOT分析
    Summary Swelect Energy Systems Ltd(SESL), is an energy company that manufactures and markets renewable energy products and iron and steel products. The company’s renewable energy products include solar pv modules, solar inverter, solar water pump and energy efficient lighting. SESL offers iron and s …
  • Repro-Med Systems Inc (REPR):企業の財務・戦略的SWOT分析
    Summary Repro-Med Systems Inc (RMS) is a medical device company that develops and manufactures home and specialty infusion solutions. The company's products include syringe infusion system, subcutaneous safety needle sets, precision flow rate tubing, and hand held medical suction products. It offers …
  • Xiangxue Pharmaceutical Co Ltd (300147):製薬・医療:M&Aディール及び事業提携情報
    Summary Xiangxue Pharmaceutical Co Ltd (XPH) is a pharmaceutical company that manufactures and distributes drugs and medicines. The company’s products include drugs, Chinese medicine pieces, medical instruments, health products and medicinal drinks, among others. It also provides healthcare suppleme …
  • CMA CGM SA:戦略・SWOT・企業財務分析
    CMA CGM SA - Strategy, SWOT and Corporate Finance Report Summary CMA CGM SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Air Canada:企業の戦略・SWOT・財務情報
    Air Canada - Strategy, SWOT and Corporate Finance Report Summary Air Canada - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Dilafor AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Dilafor AB (Dilafor) is a drug development company that develops pharmaceutical products for obstetric indications. The company offers tafoxiparin, a proprietary heparan sulfate mimetic, which is used as an adjuvant therapy to promote cervical ripening and myometrial contractility. Its tafox …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆